ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4976ometendo-4976Research ArticleСтатьиArticlesЛечение сахарного диабета 2 типа ингибиторами дипептидилпептидазы-4Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4GalstyanG Rfoot@endocrincentr.ru20101509201073№3 (2010)36Copyright © Galstyan G.R., 20102010Galstyan G.R.Galstyan G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4976

Сахарный диабет 2 типа (СД2) является сложным заболеванием, требующим многокомпонентного терапевтического воздействия. Однако наиболее сложным в ведении пациентов с СД2 является достижение оптимального контроля заболевания без увеличения риска гипогликемических эпизодов и прибавки массы тела. Ингибиторы дипептидилпептидазы-4 улучшают гликемический контроль путем повышения секреторного ответа β-клеток на глюкозу и подавления секреции глюкагона. В статье приводится анализ результатов клинических исследований эффективности использования одного из препаратов этого класса - вилдаглиптина - в монотерапии и комбинированной терапии пациентов с СД2.

Type 2 diabetes is difficult to manage and multiple therapeutic approach are usually needed. Moreover, addition to the initial treatment of most currently available oral antidiabetic agents increases the risk of hypoglycaemia and causes a weight gain. Dipeptidyl peptidase-IV inhibitors improve glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate glucagon secretion. This article summarizes the data from randomized clinical trial in which efficacy and safety of vildagliptin were assessed.

глюкагонглю- кагон-подобный пептидингибитор дипептидилпептидазы-4вилдаглиптинglucagonglucagon like peptidedipeptidyl peptidase inhibitor-IVvildagliptinReferenceswww.diabetes.org/diabetes-statistics. Last accessed 07 May 2010. www.worlddiabetesday. org/en/the-campaign/unite-for diabetes/why-diabetes. Last accessed 07 May 2010.www.diabetes.org/diabetes-statistics. Last accessed 07 May 2010. www.worlddiabetesday. org/en/the-campaign/unite-for diabetes/why-diabetes. Last accessed 07 May 2010.Ahren B. Glucagon-like peptide-1 (GLP1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20, Р. 642-651 (1998).Ahren B. Glucagon-like peptide-1 (GLP1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20, Р. 642-651 (1998).Ahren Bo. Islet G protein-coupled receprots as potential targets for treatment of type 2 diabetes. Nature reviews Drug Discovery 8 (2009), Р. 369-385.Ahren Bo. Islet G protein-coupled receprots as potential targets for treatment of type 2 diabetes. Nature reviews Drug Discovery 8 (2009), Р. 369-385.Baunck M. Function and Glycaemic control following one-year vildagliptin treatment and after 12-week washout in drug-nave patients with type 2 diabetes and mild hyperglycaemia ADA, Orlando 2010 OP 321.Baunck M. Function and Glycaemic control following one-year vildagliptin treatment and after 12-week washout in drug-nave patients with type 2 diabetes and mild hyperglycaemia ADA, Orlando 2010 OP 321.Davidson J. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 Inhibitors // Clinical Journal of Medicine, 2009; V. 76, S28-S38.Davidson J. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 Inhibitors // Clinical Journal of Medicine, 2009; V. 76, S28-S38.Dejager S., Razac S., Foley J. Vildagliptin in drug-naive patients with type 2 diabetes: 24 week RCT // Horm. Metab. Res., 2007; 39: Р. 218-223.Dejager S., Razac S., Foley J. Vildagliptin in drug-naive patients with type 2 diabetes: 24 week RCT // Horm. Metab. Res., 2007; 39: Р. 218-223.Dotta F., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-nave patients with type 2 diabetes mellitus // Diabetes Obes. Metab., 2009 11(5): Р. 506- 516; // Metab. 3, Р. 153-165 (2006).Dotta F., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-nave patients with type 2 diabetes mellitus // Diabetes Obes. Metab., 2009 11(5): Р. 506- 516; // Metab. 3, Р. 153-165 (2006).Drucker D. The biology of incretin hormones // Cell. Metab. 3, Р. 153-165 (2006).Drucker D. The biology of incretin hormones // Cell. Metab. 3, Р. 153-165 (2006).Druckner D.J. Dipeptidyl Peptidase-4 inhibition and the treatment of Type 2 Diabetes // Diabetes Care. 2007 Jun; 30(6): P. 1335-43.Druckner D.J. Dipeptidyl Peptidase-4 inhibition and the treatment of Type 2 Diabetes // Diabetes Care. 2007 Jun; 30(6): P. 1335-43.Fonseca V., Schweizer A., Albrecht M. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Jun; 50(6): P. 1148-51.Fonseca V., Schweizer A., Albrecht M. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Jun; 50(6): P. 1148-51.Garber A., Schweizer et al. Vildagliptin in combunation with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolindione monotherapy // Diab. Obes. Metab., 2007; 9: Р. 166-174.Garber A., Schweizer et al. Vildagliptin in combunation with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolindione monotherapy // Diab. Obes. Metab., 2007; 9: Р. 166-174.Goke B., Herbson et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes Horm Metab Res 2008; 40: Р. 892-895.Goke B., Herbson et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes Horm Metab Res 2008; 40: Р. 892-895.Manucci E., Pala L., Ciani S. et al. Hyperglycaemia increases DPP-IV activity in diabetes mellitus // Diabetologia 48: Р. 1168-1172, 2005.Manucci E., Pala L., Ciani S. et al. Hyperglycaemia increases DPP-IV activity in diabetes mellitus // Diabetologia 48: Р. 1168-1172, 2005.Nathan D., Buse J., Davidson M. et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of American Diabetes Association and the European Association for the Study of Diabetes // Diabetologia (2010) 52: Р. 17-30.Nathan D., Buse J., Davidson M. et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of American Diabetes Association and the European Association for the Study of Diabetes // Diabetologia (2010) 52: Р. 17-30.Nolan J.J. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia (2010) 53: Р. 1247-1249.Nolan J.J. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia (2010) 53: Р. 1247-1249.Pan C. et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 Diabetes // Diabet. Med., 2008; 25: Р. 435-441.Pan C. et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 Diabetes // Diabet. Med., 2008; 25: Р. 435-441.Pi-Suyaer F., Scweizer A., Mills D. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 Diabetes // Diab. Res. Clin. Pract., 2007; 76: Р. 132-138.Pi-Suyaer F., Scweizer A., Mills D. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 Diabetes // Diab. Res. Clin. Pract., 2007; 76: Р. 132-138.Ryskjaer J., Deacon C.F. et al. Plasma DPP-IV activity in patients with type 2 diabetes Mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake // Eur. J. of Endocrinology 155: Р. 485-493, 2006.Ryskjaer J., Deacon C.F. et al. Plasma DPP-IV activity in patients with type 2 diabetes Mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake // Eur. J. of Endocrinology 155: Р. 485-493, 2006.Schernthaner G., Barnett H., Betteridge D.J et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 53: Р. 1258-1269.Schernthaner G., Barnett H., Betteridge D.J et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 53: Р. 1258-1269.Schwiezer A., Counturier A. Foley Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-nave type 2 Diabetic patients // Diabetes Med., 2007; 24: Р. 955-961.Schwiezer A., Counturier A. Foley Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-nave type 2 Diabetic patients // Diabetes Med., 2007; 24: Р. 955-961.VilsbШll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus // Diabetologia, 2004; 47(3): Р. 357-366.VilsbШll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus // Diabetologia, 2004; 47(3): Р. 357-366.

The authors declare that there are no conflicts of interest present.